Friedberg explains Yamanaka factors are first targeting specific diseases like blindness before systemic treatment.
“They're starting with targeting diseases, like a particular like like blindness or glaucoma in the eye or, you know, rheumatoid arthritis or some other heart issue, and they're applying these factors to the cells in that tissue only.”
Friedberg states extending lifespan by one year adds tens of trillions to GDP.
“For every one year, we can extend average human lifespan. We're adding tens of trillions of dollars to GDP. Right? So this is also another big economic driver.”
Friedberg reports longevity cocktails are already in clinical trials with human cells tested in vitro.
“And if there's always a risk in going from animals to humans, but we've done it with human cells in in vitro, in a in a petri dish,”